Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Mueller, Susanne ^a   Holdenrieder, Stefan ^a   Stieber, Petra ^a   Haferlach, Torsten ^a   Schalhorn, Andreas ^a   Braess, Jan ^a   Nagel, Dorothea ^a   Seidel, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS DNA; CYTARABINE; DAUNORUBICIN; DNA FRAGMENT; LACTATE DEHYDROGENASE; MITOXANTRONE; THYMIDINE KINASE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; BONE MARROW HYPOPLASIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE; MALE; NUCLEOSOME; PREDICTION; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DNA FRAGMENTATION; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID; LEUKOCYTES; MALE; MIDDLE AGED; MITOXANTRONE; NUCLEOSOMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; THIOGUANINE; THYMIDINE KINASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33748051055     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-143     Document Type: Article

References (54)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EF, Edwards BK: SEER Cancer Statistics Review, 1975-2001. National Cancer Institute 2004 [http://seer.cancer.gov/csr/1975_2002/].
2. Ferrara F: Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004, 5:443-450.
3. Stone RM, O'Donnell MR, Sekeres MA: Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004:98-117.
4. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A: Double inductin strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group. Blood 1999, 93:4116-4124.
5. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH, on behalf of the Medical Research Council Adult Leukemia Working Party: The predictive value of hierarchical cytogenetic classification in older patients with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001, 98:1312-1320.
6. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, Wandt H, Aulitzky W, Bodenstein H, Sonnen R, Link H, Ehninger G, Gramatzki M, AML-SHG Study Group: Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003, 53:11-19.
7. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD: Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004, 28:43-48.
8. Nannya Y, Kanda Y, Oshima K, Kaneko M, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Matsuyama T, Takezako N, Miwa A, Togawa A: Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan. Leuk Lymphoma 2002, 43:83-87.
9. Kern W, Haferlach T, Schoch C, Loeffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buechner T, Hiddemann W: Early blast clearance by remission induction therapy is major independent prognostic factor for both achievment of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML-Cooperative Group (AMLCG) 1992. Blood 2003, 101:64-70.
10. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990, 40:2353-2362.
11. Debatin KM: The role of CD 95 system in chemotherapy. Drug Resist Updat 1999, 2:85-90.
12. Petak I, Houghton JA: Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001, 7:95-102.
13. Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM: Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003, 17:2130-2139.
14. Halicka HD, Seiter K, Feldman EJ, Traganos F, Mittelman A, Ahmed T, Darzynkiewicz Z: Cell cycle specificity of apoptosis during treatment of leukemia. Apoptosis 1997, 2:25-39.
15. Wyllie AH, Bellamy CO, Bubb VJ, Clarke AR, Corbet S, Curtis L, Harrison DJ, Hooper ML, Toft N, Webb S, Bird CC: Apoptosis and carcinogenesis. Br J Cancer 1999, 80(S1):34-37.
16. Enari M, Sakahira H, Yokoyamo H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:96-99.
17. Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G: The apoptosis endonuclease and its regulation. Semin Immunol 1992, 4:389-397.
18. Arends MJ, Morris RG, Wyllie AH: Apoptosis. Am J Pathol 1990, 136:593-608.
19. Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1999, 73:2013-2026.
20. Rumore P, Mavalidhar B, Lin B, Lai C, Steinman CR: Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol 1992, 90:56-62.
21. Lo YMD, Tein MSC, Pang CCP, Yeung CK, Tong KL, Hjelm NM: Presence of donor-specific DNA in plasma of kidney and liver transplant recipients. Lancet 1998, 351:1329-1330.
22. Holdenrieder S, Stieber P, Bodenmueller H, Fertig G, Fuerst H, Schmeller N, Untch M, Seidel D: Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001, 39:596-605.
23. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
24. Shapiro B, Chakrabarty M, Cohn EM, Leon SA: Determination of circulating DNA levels in patients with benign and malignant gastrointestinal disease. Cancer 1983, 51:2116-2120.
25. Kuroi K, Tanaka C, Toi M: Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol 2001, 19:143-148.
26. Holdenrieder S, Stieber P, Foerg T, Kuehl M, Schulz L, Busch M, Schalhorn A, Seidel D: Apoptosis in serum of patients with solid tumours. Anticancer Res 1999, 19:2721-2724.
27. Holdenrieder S, Stieber P, Bodenmueller H, Busch M, Fertig G, Fuerst H, Schalhorn A, Schmeller N, Untch M, Seidel D: Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001, 95:114-120.
28. Holdenrieder S, Stieber P, Bodenmueller H, Busch M, von Pawel J, Schalhorn A, Nagel D, Seidel D: Circulating nucleosomes in serum. Ann N Y Acad Sci 2001, 945:93-102.
29. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:5981-5987.
30. Mueller M: P53 activates the CD95 (Apo-I/Fas) gene in response to DNA-damage by anticancer therapy. J Exp Med 1998, 188:2033-2045.
31. Stahnke K, Fulda S, Friesen C, Strauß G, Debatin KM: Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 2001, 98:3066-3073.
32. Braess J, Schneiderat P, Schoch C, Fiegl M, Lorenz I, Hiddemann W: Functional analysis of apoptosis induction in acute myeloid leukaemia - relevance of karyotype and clinical treatment response. Br J Haematol 2004, 126:338-347.
33. Fournie GJ, Courtin JP, Laval F, Chale JJ, Pourrat JP, Pujazen MC, Lauque D, Carles P: Plasma DNA as a marker of cancerous cell death. investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995, 91:221-227.
34. Kuroi K, Tanaka C, Toi M: Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer 1999, 6:361-364.
35. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L: Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
36. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelozi G, Pierotti MA, Pastorino U: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003, 21:3902-3908.
37. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, Godfrey TE: Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005, 51:113-118.
38. Anker P, Mulcahy H, Chen XO, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
39. Johnson PJ, Lo YMD: Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002, 48:1186-1193.
40. Wu TL, Zhang D, Chia JH, Tsao KC, Sun CF, Wu JT: Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002, 321:77-87.
41. Lo YMD, Chan LYS, Lo KW, Leung SF, Zhang J, Chan ATC, Lee JCK, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191.
42. Lei KIK, Chan LYS, Chan WY, Johnson PJ, Lo YMD: Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002, 8:29-34.
43. Au WY, Pang A, Choy C, Chim CS, Kwong YL: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004, 104:243-249.
44. Kornberg RD, Lorch Y: Twenty-five years of the nucleosome, fundamental particle of eukaryote chromosome. Cell 1999, 98:285-294.
45. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R: DNA fragments in blood plasma of cancer patients: quantitation and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
46. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YMD: Molecular characterization of circulating EBV-DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003, 63:2028-2032.
47. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, Johnson PJ, Lo YMD: Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002, 48:1212-1217.
48. Holdenrieder S, Stieber P, Chan LYS, Geiger S, Kremer A, Nagel D, Lo YMD: Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 2005, 51:1544-1546.
49. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D: Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol 2005, 26:44-49.
50. Carbonari M, Cibati M, Cherchi M, Sbarigia D, Pesce AM, Dell'Anna L, Modica A, Fiorilli M: Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. Blood 1994, 83:1268-1277.
51. Nieuwenhuijze van AE, van Lopik T, Smeenk RJ, Aarden LA: Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann Rheum Dis 2003, 62:10-14.
52. Gauthier VJ, Tyler LN, Mannik M: Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 1996, 156:1151-1156.
53. Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier KM, Muller MM: Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem 2004, 50:1668-1670.
54. Jahns-Streubel G, Reuter C, auf der Landwehr U, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W: Activity of thymidine kinase and of polymerase α as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 1997, 90:1968-1976.